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Apoptosis is a morphologically recognizable path-
way of cell death that occurs in a variety of physiolog-
ic processes including organogenesis,1 immunoregula-
tion,2 and tissue homeostasis.3,4 It is implemented by
a regulatory cascade that has been largely conserved
from the nematode Caenorhabditis elegans, in which it
was first studied, to humans.5 Although the molecular
basis of apoptosis is complex, its regulatory pathways
converge on a common cell death effector mechanism
orchestrated by a family of cysteine endoproteases
called caspases.6 Recent synthesis of specific caspase
inhibitors allows for controlled molecular manipula-
tion of apoptotic cell death.7
Apoptosis has a role in a wide array of patho-
physiologic states. Excess cell apoptosis has been
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observed in certain autoimmune8 and neurodegen-
erative diseases,9,10 and defective apoptosis has been
described in certain lymphoproliferative disorders11
and cancers.12
Apoptosis also occurs in tissue ischemia. It has
been described in endothelial cells exposed to
hypoxia-reperfusion conditions in situ13 and has
been noted in animal ischemia-reperfusion (IR)
models of the brain,14,15 spinal cord,16 heart,17 kid-
ney,18 retina,19 liver,20 and intestine.21,22 In murine
brain, ischemic infarction caused by transient middle
cerebral artery occlusion was characterized by a cen-
tral area of neuronal necrosis that was surrounded by
a penumbra of neurons undergoing apoptosis.
Administration of caspase inhibitors in this model
resulted in a significant reduction in infarction vol-
ume with improved neurologic recovery.15
Small bowel ischemia is a disorder that occurs not
only in a number of disease processes but also during
a variety of operations involving the abdominal aorta.
We hypothesized that apoptosis may contribute to
intestinal cell death in a similar way as has been
shown to occur in the brain, and that treatment with
a specific apoptosis inhibitor would reduce the extent
of tissue injury. To study this, we developed a seg-
mental small bowel IR model in mice.
MATERIAL AND METHODS
Animal model. Ten- to 14-week-old, 20 to 25
g C57Bl6 X SV129 mice (Jackson Labs, Bar Harbor,
Maine) were anesthetized using 2.0% halothane and
maintained on 0.6% to 1.0% halothane in 30% oxy-
gen using a Fluotec 4 vaporizer (Ohio Medical
Products, Madison, Wis). The abdomen was then
shaved and prepared with povidone iodine. A lower
midline laparotomy was performed, and the terminal
ileum was gently eviscerated. A mesenteric arteriole
feeding 8 to 10 cm of terminal ileum was identified,
isolated, and clamped with a bulldog microclamp
(Vascu-Statt; Scanlan, St Paul, Minn) that delivered
10 to 25 g/cm2 of pressure. This 8- to 10-cm seg-
ment of bowel represents approximately 20% of the
mouse small intestine. To interrupt collateral circu-
lation, a vessel loop (Scanlan) was circumferentially
tied around the proximal and distal aspects of the
isolated small bowel segment and fastened with a
medium titanium ligating clip (Horizon, Weck
Closure Systems, Research Triangle Park, NC). The
edges of the bowel segment were marked with small
titanium ligating clips (Horizon).
Ischemic interval was measured from the time of
clamping of the mesenteric arteriole until reperfu-
sion. The animal’s abdomen was closed with a run-
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ning nylon suture, a 1-mL subcutaneous warm
saline fluid bolus was administered, and the mouse
was allowed to wake up. Three minutes before the
termination of the ischemic interval the animal was
again anesthetized with halothane. The abdominal
incision was reopened, the arteriolar clamp was
removed, and the bowel vessel loops were untied.
Timing of the reperfusion interval was initiated
when the arteriolar clamp was removed. The animal
was given a second 1-mL subcutaneous warm saline
fluid bolus and allowed to awaken.
In one set of experiments the ischemic interval
was varied from 30 to 130 minutes, and the reper-
fusion interval was kept constant at 6 hours. In
another set of experiments the ischemic interval was
kept at 50 minutes, and the reperfusion interval was
varied from 6 to 24 hours (data not shown). Pilot
studies demonstrated maximal ischemic injury after
6 hours of reperfusion as compared with 24 hours;
therefore the shorter reperfusion time interval was
selected for future caspase inhibition studies.
At the end of the designated reperfusion inter-
val mice were killed using cervical dislocation, the
abdominal cavity was opened, and the previously
marked ischemic small bowel, as well as a 10-cm
nonischemic segment, were harvested. Sham con-
trol mice underwent similar operations with small
bowel dissection but no mesenteric blood flow
interruption.
Adequacy of IR was assessed and found to be
complete using tail vein fluorescein (Alcon Labs,
Fort Worth, Texas) injections in three animals.
Fluorescein was not visualized in the isolated bowel
segment during ischemia, when the mesenteric arte-
riole subserving it was clamped, but was observed
during reperfusion, when the clamp was removed.
In addition, ischemia and reperfusion were con-
firmed in every animal by the findings of absent
mesenteric arteriolar blood flow using a laser flow
blood perfusion monitor (TSI Inc, St Paul, Minn).
Unclamped arterioles were routinely measured to
have flow rates of 100 to 120 mL/min/100 g tis-
sue, whereas flow in clamped vessels was less than 20
mL/min/100 g tissue.
Animal experiments were approved by the
Dartmouth Medical School Institutional Animal
Care and Use Committee and complied with the
“Guide for the Care and Use of Laboratory Animals”
(National Institutes of Health, Washington, DC).
Drug treatment. N-benzyloxycarbonyl Val-Ala-
Asp-Ome-fluoromethylketone (ZVAD) (Enzyme
Systems Products, Dublin, Calif) is a broad spec-
trum, irreversible, competitive caspase antagonist.7
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N-benzyloxycarbonyl Phe-Ala fluoromethylketone
(ZFA) (Enzyme Systems Products) is a peptide acy-
loxyfluoromethylketone cathepsin B inhibitor with
no known anticaspase activity (placebo). Before each
experiment, both compounds were dissolved fresh in
dimethyl sulfoxide (Fisher-Scientific, Fair Lawn, NJ)
at 100 mg/mL and then diluted 1:100 in a lipid car-
rier (CPC International, Englewood Cliffs, NJ).
Caspase inhibitor experiments were conducted
using 50-minute ischemia and 6-hour reperfusion
intervals. These were chosen because they yielded a
moderate level of tissue injury in which, on the aver-
age, the basic integrity of the bowel mucosa was pre-
served. ZVAD (caspase inhibitor), ZFA (placebo),
or carrier alone was administered to mice in divided
doses over a series of five injections (Fig 1). The first
two doses (0.5 mg) were administered subcuta-
neously in 0.5 mL of carrier 1 hour before and
immediately preceding mesenteric ischemia. The
third dose (1 mg) was administered intraperitoneal-
ly immediately on reperfusion. The last two doses
(0.5 mg) were given subcutaneously 1 and 2 hours
after the onset of reperfusion.
Specimen preparation. Harvested bowel seg-
ments were flushed with saline, immersion-fixed in
10% neutral buffered formalin (Sigma, St Louis, Mo)
for 1.5 hours at room temperature, and rinsed in 
0.1 mol/L phosphate-buffered saline, pH 7.4 (Fisher-
Scientific). Samples were stored in phosphate-
buffered saline overnight at 4°C and dehydrated in
ethanol (Sigma). The central 4-cm segments of
ischemic and normal specimens, deemed to be far-
thest away from arteriolar blood flow and therefore
most susceptible to ischemic injury, were chosen for
further analysis. They were embedded in paraffin
(Fisher-Scientific) and then cut into 5-µm sections.
Histologic analysis. Paraffin sections were
stained with hematoxylin-eosin, and two separate
sections of each bowel segment were evaluated under
a Nikon microscope using 40× magnification by two
independent observers blinded to the source of the
slides. Using a well-established grading scheme,23
the histologic sections were visually split into quar-
ters and graded 1 to 5 (Fig 2). Grade 1 represented
normal mucosal villi. Grade 2 represented develop-
ment of mucosal slough at villous tips. Grade 3 rep-
resented extension of the subepithelial space with the
epithelial layer lifting up in sheets, presence of a few
denuded villous tips, and mild capillary congestion.
Grade 4 represented denuded villi with exposed lam-
ina propria; dilated, exposed capillaries with evidence
of hemorrhage; and increased cellularity of the lami-
na propria. Grade 5 represented digestion and disin-
tegration of the lamina propria in villi and presence of
hemorrhage and ulceration.
The histologic injury grade for each quarter was
averaged to represent the grade for each section, and
grades for each of the two sections were averaged for
each animal. Finally, injury grade values given by
two observers, blinded to the source of the slides,
were combined to yield the final histologic injury
grade for each animal.
Apoptosis was measured in tissue embedded in
paraffin and subjected to terminal deoxynucleotydil
transferase-mediated dexoyuridine triphosphate-
biotin nick end labeling (TUNEL) (ApopTag;
Oncor, Gaithersburg, Md). This technique allows
for staining of the stereotypical 180 base pair DNA
Fig 1. Time course of experiment demonstrating inhibitor (ZVAD), placebo (ZFA), or carri-
er dosing schedule, operative intervention, and physiologic insult (ischemia, reperfusion). 
sc, Subcutaneously; ip, intraperitoneally.
JOURNAL OF VASCULAR SURGERY
Volume 30, Number 4 Farber et al 755
fragments that are produced in cells undergoing
apoptosis. Sections were viewed by two observers
blinded to the source of the slides, and apoptotic
cells were identified. An apoptotic index was defined
as the number of apoptotic cells counted per 10 con-
tiguous, high-power fields. Only apopotoses of cells
in the mucosa that morphologically looked like
epithelial cells were counted.
Interleukin-1β determination. Mature inter-
leukin-1β (IL-1β) levels present in bowel were 
measured using an enzyme-linked immunosorbent
assay (ELISA) kit (Genzyme, Cambridge, Mass) as
described by the manufacturer. Four-centimeter
portions of ischemic and normal small bowel were
harvested and mechanically digested for 20 seconds
using a Teflon pistle wheaton tissue grinder (VWR
Scientific, Boston, Mass) in phosphate-buffered
saline (0.1 mol/L, pH 7.4, 4°C) containing 2
mmol/L phenylmethylsulfonyl fluoride, 1 µg/mL
leupeptin, 1 µg/mL antipain, 1 µg/mL aprotinin, 1
µg/mL pepstatin, 0.05% (wt/vol) sodium azide, 4
mmol/L ethylenediaminetetraacetic acid (Sigma),
Fig 2. Representative hematoxylin-eosin stained sections of small bowel showing histologic
intestinal injury grading.23 (Original magnification ×40, Nikon microscope). Grade 1, Normal
mucosal villi; grade 2, development of mucosal sloughing; grade 3, epithelial layer lifting up in
sheets, presence of a few denuded villous tips, and mild capillary congestion; grade 4, exposed
lamina propria, dilated capillaries, and evidence of hemorrhage; grade 5, digestion and disinte-
gration of the lamina propria.
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and 0.05 mg/mL of ZVAD. The suspension was
then centrifuged (30 minutes, 50,000g, 4°C), the
supernatant was harvested, and 100 µL samples
were used for each ELISA assay.
Statistical analysis. Data analysis was performed
using Student t test for the apototic index calculation
and IL-1β determinations. Nonparametric statistical
analyses (Kruskall-Wallis, Mann-Whitney tests) and
parametric analysis using ANOVA with Fisher post
hoc tests were both performed to evaluate the statis-
tical significance of the results of the ZVAD/ZFA
experiments. Statistical analysis was performed using
a specialized computer program (Stata Statistical
Software 5.0, College Station, Texas).
RESULTS
Effect of IR on intestinal viability. Mice that
underwent small bowel ischemia appeared more
lethargic than animals subjected to sham operations.
As the period of ischemia was lengthened from 30 to
130 minutes (with a constant 6-hour reperfusion
interval), the degree of histologic injury to the
ischemic segment of small bowel increased steadily
until the maximal degree of injury was achieved after
110 minutes (Fig 3; r = 0.69, P < .006).
Effect of IR on apoptosis. Background apop-
tosis was noted in normal small bowel of sham con-
trols (apoptotic index, 11 ± 2) and in the normal
bowel of animals subjected to mesenteric ischemia
(apoptosis index, 13 ± 6). Mesenteric ischemia was
associated with increased apoptotic index as mea-
sured using the TUNEL assay. Fifty minutes of
mesenteric ischemia caused the apoptotic index to
rise from 11 ± 2 to 56 ± 9, which represents a
greater than fivefold increase (P = .05) (Fig 4).
Apoptotic index peaked at 70 minutes of ischemia
and decreased thereafter. Moderate to severe tissue
injury caused sloughing of a significant number of
cells into the bowel lumen. This intraluminal cell
loss was responsible for a lower than expected apop-
totic index noted in grades 3 to 5 injury (data not
shown).
Mature IL-1β was used to assay IL-1β convert-
ing enzyme (ICE) activity and therefore apoptosis.
Ischemic bowel had 57.3 ± 7.8 pg/mL of mature
IL-1β, whereas normal bowel had on the average
1.8 ± 0.5 pg/mL (P < .05) (Fig 5), indicating that
ICE is activated in ischemic small bowel.
Effect of caspase inhibition on intestinal via-
bility. To test the hypothesis that ICE activation
and therefore apoptosis are important in ischemia-
mediated tissue injury, we evaluated whether ZVAD,
a specific caspase inhibitor, would reduce small
bowel injury.
Mice tolerated multiple injections of ZVAD and
ZFA without overt signs of toxicity such as lethargy,
weakness, poor drinking, or poor ambulation.
Animals treated with the caspase inhibitor ZVAD
had a similar histologic grade after 50 minutes of
ischemia and 6 hours of reperfusion (injury grade,
1.8) as compared with sham controls (injury grade,
1.2; P = .7), and had significantly less injury com-
Fig 3. Correlation between duration of ischemic interval and magnitude of histologic injury (n
= 4 animals/time point; 6 hours of reperfusion; r = 0.69; mean ± standard error of the mean).
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pared with mice treated with the placebo ZFA
(injury grade, 3.0; P < .006) (Fig 6). Statistical sig-
nificance was demonstrated using nonparametric
(Kruskall-Wallis and Mann-Whitney tests) and para-
metric statistical analyses (ANOVA with Fisher ad
hoc tests).
DISCUSSION
Apoptotic cell death has been recently shown to
have a central role in many physiologic and patho-
physiologic processes.1-4,8-12 Although the apoptot-
ic cascade is complex and its regulation is not com-
pletely understood, it has become clear that a family
of cysteine endoproteases called caspases plays a crit-
ical role in the execution of apoptotic cell death.
Recently, specific caspase inhibitors called acyloxy-
fluoromethylketones have been synthesized and
demonstrated to act as irreversible, competitive cas-
pase antagonists.7 These compounds have been
shown to inhibit apoptosis caused by a variety of
stimuli in a number of in vitro24,25 and in vivo mod-
els.15 Acyloxyfluoromethylketones have been used
in vivo to successfully block apoptosis and decrease
tissue injury in Fas-mediated liver failure.26
Apoptosis can be evoked by a number of differ-
ent stimuli including tissue IR. In vitro and in vivo
models of IR demonstrate the presence of cells
undergoing apoptosis.14,16-22 Recently, apoptosis
has been described in ischemic brain infarction in a
rodent model of middle cerebral artery occlusion.
Administration of acyloxyfluoromethylketone cas-
pase inhibitors in that model resulted in a significant
reduction in brain infarction volume and improved
neurologic recovery.15
Apoptosis occurs in normal bowel27,28 and has
been described in several murine superior mesenteric
artery (SMA) occlusion models.21,22 It was our goal
to study the role of apoptosis in intestinal IR and to
evaluate the effects of apoptosis inhibition on intesti-
nal viability. To limit the effects of systemic injury
induced by total SMA occlusion, we developed a
segmental small bowel IR model in mice based on a
previously described model in rats.29 In several
experiments we varied the length of mesenteric
ischemia while maintaining the duration of reperfu-
sion constant at 6 hours (Fig 3). The degree of his-
tologic injury increased with increasing ischemia and
was maximal at 110 minutes of ischemia. This cor-
relation was similar to that described in our rat
model.30 In experiments in which reperfusion was
varied between 20 minutes and 24 hours, in the face
of a constant 50-minute ischemia interval, 6 hours
of reperfusion was found to cause a maximal degree
of injury (data not shown). Fifty minutes of ischemia
and 6 hours of reperfusion were chosen because
these time points yielded sufficient but not excessive
degree of tissue injury. They were used for all subse-
quent experiments.
Increasing ischemia, in the face of fixed reperfu-
sion, correlated with increased intestinal apoptosis.
Fig 4. Relationship between apoptotic index (apoptotic cells/10 high-power fields) and dura-
tion of ischemic interval (n = 4/time point; mean ± standard error of the mean; *P ≤ .05 com-
pared with sham controls, Student t test).
JOURNAL OF VASCULAR SURGERY
758 Farber et al October 1999
Histologic analysis using the TUNEL assay revealed
that bowel harvested from sham controls had a low
background apoptosis level consistent with previous-
ly described results.31 Mesenteric ischemia resulted
in significantly increased apoptosis that was maximal
at 70 minutes of ischemia (Fig 4). Our apoptotic
index of 56 ± 9, noted after 50 minutes of ischemic
injury, is similar to the level of apoptosis observed in
a murine SMA occlusion model.21
Although mild degrees of tissue injury allowed
for accurate quantification of the apoptotic index,
moderate to severe tissue injury made this value dif-
ficult to quantify. Increased shedding of necrotic and
apoptotic cells into the bowel lumen yielded a lower
apparent apoptotic index than would be expected.
This cell loss associated with bowel injury limited
our ability to accurately quantify the degree of apop-
tosis in the samples with most severe injury (injury
grades 4 and 5).
To further quantify the degree of apoptosis
occurring in ischemic bowel, we assessed our sam-
ples for ICE activation. Because ICE is activated in
apoptotic cell death32-35 and is the only protease in
mice that cleaves pro-IL-1β into its mature
form,33,35,36 we measured mature IL-1β levels in
our bowel samples as a surrogate for ICE activity
and apoptosis. Normal bowel had minimal mature
IL-1β levels correlating with low level of TUNEL
staining, indicating little apoptosis. It has been
shown that human small bowel exposed to ex vivo
IR releases IL-1β.37 In our model, ischemic bowel
had significantly increased mature IL-1β levels, indi-
cating ICE activation, and increased apoptosis by
TUNEL assay. We believe that this may be the first
instance in which ICE activation has been correlated
both with increased apoptosis, as evidenced by the
TUNEL assay, and with increased histologic evi-
dence of tissue injury.
Having demonstrated that increasing ischemia
from 0 to 70 minutes was associated with increased
apoptosis, we treated animals undergoing segmental
bowel IR with the broad-spectrum caspase inhibitor
ZVAD or the placebo ZFA. In other animal studies,
microgram and nanogram quantities of ZVAD in
dimethyl sulfoxide have been used intravenously26
and intracerebroventricularly.15 Because similar
quantities of ZVAD did not yield positive results in
our model, we administered milligram amounts of
this compound to our animals (Fig 1). Mice tolerat-
ed subcutaneous and intraperitoneal injections of
these substances in a lipid carrier without signs of
systemic toxicity. Mice treated with the caspase
inhibitor ZVAD had significantly less intestinal
injury compared with mice given the placebo ZFA.
In fact, injury was so well prevented by ZVAD that
there was no significant difference in injury between
mice receiving ZVAD and sham controls that did
not undergo ischemia. This finding was reproduced
in two separate experiments using 26 mice.
We measured apoptosis by the TUNEL assay and
Fig 5. Determination of mature IL-1β in ischemic and
normal small bowel specimens. Mature IL-1β was deter-
mined from mechanically and enzymatically digested
bowel using a specific ELISA assay (n = 6/group; mean
concentration ± standard error of the mean; P < .05,
Student t test).
Fig 6. Effect of apoptosis inhibitor (ZVAD) and placebo
(ZFA) on histologic injury grade after 50 minutes of
ischemia and 6 hours of reperfusion. Apoptosis inhibition
(ZVAD) markedly reduced injury compared with placebo
(ZFA) to the extent that it was statistically similar to sham
injury (P = .7; n = 11, ZVAD; n = 9, ZFA; n = 6, sham
controls; mean ± standard error of the mean; Kruskall-
Wallis, Mann-Whitney, ANOVA with Fisher ad hoc tests).
tissue mature IL1β determination in our ZVAD and
ZFA treated animals and were initially surprised to
detect no difference despite marked differences in
histology; however on further analysis, we postulate
that this is most likely due to technical limitations.
In distinction to other organ systems, increased his-
tologic injury to small bowel is associated with
progessive cell loss into the bowel lumen where
these cells are washed away and thereby are not
included in the analysis. This results in underestima-
tion of the apoptotic cell count and mature IL-1β
level measurements because the only remaining cells
in the severely injured segment are focal groups that
have avoided injury. We always observed nonuni-
form histologic injury in ischemic bowel sections,
and this was increased with severe ischemia. We
believe that this may explain our observation that
the significantly more injured bowel from mice
treated with the placebo ZFA had apparently similar
apoptotic index and mature IL-1β levels as mice
treated with the inhibitor ZVAD that had less tissue
injury. This issue underscores an intrinsic problem
with bowel ischemia (injured cells not available for
analysis because of sloughing into lumen) and the
relative paucity of assays that are available to direct-
ly quantify apoptosis in vivo. There is little doubt
that these latter limitations will be overcome as more
is learned about this process.
In these experiments we have demonstrated that
intestinal IR is associated with tissue injury, cell
death, and activation of the apoptotic cascade.
Caspase antagonists have been shown by others to
inhibit this cascade in vitro and in vivo.15,24-26,34 In
our segmental intestinal IR model these apoptosis
inhibitors have significantly and reproducibly dimin-
ished tissue injury. These inhibitors likely have little
effect on cells most injured by IR, which go on to
die by the process of necrosis. However, they may
allow for rescue of a population of cells that are
moderately injured and undergoing the process of
apoptosis. It is these cells that have the potential to
recover from their injury once the deleterious stim-
ulus is removed. Although in severe injury necrosis
may play a major role, in lesser degree of injury
apoptosis is clearly significant.
In the clinical setting, salvage of certain popula-
tions of injured cells may have significance in terms of
organ function and the systemic effects of tissue injury.
Inhibition of cell death in acute intestinal ischemia syn-
dromes may not only decrease the amount of bowel
that requires resection but also may affect the severity
of the systemic inflammatory response that so often
accompanies mesenteric ischemia. In addition, specific
inhibition of apoptotic pathways may be useful in
intestinal and visceral organ preservation during
ischemia induced by certain aortic or mesenteric vas-
cular operative procedures.
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